Volitionrx LTD Form 4 insider transactions

Rodney Gerard Rootsaert, a Secretary at VolitionRX Ltd, reported acquiring 11,000 shares of common stock on August 15, 2024, as part of a restricted stock unit (RSU) vesting.

CEO Salvatore Thomas Butera of VolitionRx Ltd. acquired shares through the vesting of restricted stock units (RSUs) and had unvested units cancelled.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx, reports acquisition of shares due to vesting of restricted stock units (RSUs).

Cameron John Reynolds, CEO of VolitionRx Ltd, reports the vesting of 29,500 restricted stock units (RSUs) and the cancellation of 38,350 RSUs due to unmet performance goals.

Director Alan Colman reports the vesting of 5,000 restricted stock units and cancellation of 6,500 restricted stock units in VolitionRX Ltd.

Chief Financial Officer of VolitionRx, Terig Hughes, reports the vesting of restricted stock units and cancellation of unvested units.

Director Mickie Henshall reports the vesting of 5,000 restricted stock units and cancellation of 6,500 RSUs in VolitionRX Ltd.

Chief Operating Officer of VolitionRx, Gaetan Michel, reports vesting of restricted stock units and cancellation of unvested units.

Director Guy Archibald Innes transferred 400,000 VolitionRX shares to The Innes Family Bare Trust 2023 and another 400,000 shares to The Dill Faulkes Educational Trust Limited on July 4, 2024.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRX Ltd, received 11,685 restricted stock units (RSUs) in lieu of cash compensation on June 1, 2024.

Director Alan Colman received 12,016 restricted stock units (RSUs) from VolitionRx Ltd in lieu of cash compensation on June 1, 2024.

Andrew Retter, Chief Medical Officer of VolitionRx Ltd, received 8,326 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Cameron John Reynolds, CEO of VolitionRx Ltd, received 90,182 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Gael Forterre, Chief Commercial Officer of VolitionRx, received 8,944 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Gaetan Michel, Chief Operating Officer of VolitionRX Ltd, received 13,689 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Director Guy Archibald Innes of VolitionRX Ltd. receives 16,022 restricted stock units (RSUs) in lieu of cash compensation, according to a recent SEC filing.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, received 40,709 restricted stock units (RSUs) in lieu of cash compensation on June 1, 2024.

Jasmine Kway, CEO Singapore of VolitionRx Ltd, reports acquiring 13,570 shares of common stock on June 1, 2024, through restricted stock units (RSUs) in lieu of cash compensation.

Director Kim Nguyen reports acquiring 8,011 shares of VolitionRX common stock on June 1, 2024, through restricted stock units (RSUs) in lieu of cash compensation.

Terig Hughes, CFO of VolitionRX Ltd, received 11,686 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Salvatore Thomas Butera, CEO of Volition Veterinary (a subsidiary of VolitionRx Ltd), received 31,256 restricted stock units (RSUs) in lieu of cash compensation and disposed of 99,350 shares of common stock.

Nicholas Plummer, GC of VolitionRx, received 10,249 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Director Phillip Barnes acquired 8,011 shares of VolitionRx Ltd. common stock on June 1, 2024, in lieu of cash compensation.

Rodney Gerard Rootsaert, Secretary of VolitionRx Ltd, received 12,984 restricted stock units (RSUs) on June 1, 2024, in lieu of cash compensation.

Chief Medical Officer of VolitionRx, Andrew Retter, reports acquiring 100,000 shares of common stock as part of a restricted stock unit (RSU) grant.

CEO Salvatore Thomas Butera of VolitionRx Ltd. reports disposition of shares to cover tax obligations related to restricted stock units.